Canopy Growth Corporation (CGC)
NASDAQ: CGC · Real-Time Price · USD
1.445
+0.065 (4.71%)
Sep 5, 2025, 3:19 PM - Market open
Canopy Growth Revenue
Canopy Growth had revenue of 72.13M CAD in the quarter ending June 30, 2025, with 8.94% growth. This brings the company's revenue in the last twelve months to 274.92M, down -4.24% year-over-year. In the fiscal year ending March 31, 2025, Canopy Growth had annual revenue of 269.00M, down -9.47%.
Revenue (ttm)
274.92M CAD
Revenue Growth
-4.24%
P/S Ratio
2.14
Revenue / Employee
286,372 CAD
Employees
960
Market Cap
430.55M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 269.00M | -28.15M | -9.47% |
Mar 31, 2024 | 297.15M | -36.11M | -10.83% |
Mar 31, 2023 | 333.25M | -142.45M | -29.94% |
Mar 31, 2022 | 475.70M | -70.95M | -12.98% |
Mar 31, 2021 | 546.65M | 147.88M | 37.08% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CGC News
- 1 day ago - Leading Independent Proxy Advisory Firm ISS Recommends Canopy Growth Shareholders Vote FOR All Resolutions - Business Wire
- 2 days ago - 3 Top Canadian Marijuana Stock Choices For A Possible Breakout In 2025 - MarijuanaStocks
- 6 days ago - Canopy Growth Establishes New US$200 Million At-The-Market Program to Strengthen the Company's Financial Position - Business Wire
- 9 days ago - Canopy USA Welcomes Cannabis Veteran Eric Ruhle as New Vice President of Brand Sales - PRNewsWire
- 10 days ago - Top Canadian Marijuana Stocks to Watch in 2025 : Industry Growth and Legalization Updates - MarijuanaStocks
- 18 days ago - Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market - PRNewsWire
- 19 days ago - Best Canadian Cannabis Stocks in 2025 - MarijuanaStocks
- 21 days ago - Canopy Growth Announces Mailing and Filing of Proxy Materials for Annual General and Special Meeting and Urges All Shareholders to Vote Now - Business Wire